Regulus Therapeutics announces the timing of the webcast and conference call on the financial results for the second quarter of 2021
SAN DIEGO, Aug. 3, 2021 / PRNewswire / – Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative drugs against microRNAs (the “Company” or “Regulus”), announced today that it will publish financial results and highlights for the past quarter June 30, 2021 on Tuesday, August 10, 2021, after the US financial markets close.
The company will host a conference call and live audio webcast on Tuesday, August 10, 2021 at 5:00 p.m. Eastern Daylight Time report its financial results for the second quarter of 2021 and provide a company update. To access the call, please dial (877) 257-8599 (domestic) or (970) 315-0459 (international) and refer to the conference ID 2825907. To access the replay of the call over the phone, dial (855) 859-2056 (domestic) or (404) 537-3406 (international), passcode ID 2825907. The webcast and replay will be archived on the company’s website at www.regulusrx.com after the call.
Wedbush PacGrow Healthcare Conference
In addition, the company announced that Jay Hagan, President and Chief Executive Officer, will attend a panel discussion at the Wedbush PacGrow Healthcare Conference 2021 Wednesday 11th August 2021, at 4:05 p.m. ET
A live webcast of the panel will be available in the Investor Relations section of the company’s website at www.regulusrx.com. A recording of the webcast is archived 30 days after the date of presentation.
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative drugs against microRNAs. Regulus has used its expertise in the discovery and development of oligonucleotide drugs to develop a pipeline that is complemented by extensive intellectual property in the field of microRNA. Regulus has its headquarters in San Diego, CA.
Statements made in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to clinical activities related to the RGLS4326 program, including the preliminary biomarker , Pharmacokinetic and safety data obtained from the first cohort of patients in the ongoing clinical trial, the amount of data required to resume clinical trials for long-term dosing, the timing of the Company’s interactions with the FDA regarding the clinical suspension, the Timing and other preclinical and clinical activities and the company’s expected cash runway. Because such statements are subject to risks and uncertainties, actual results could differ materially from those expressed or implied in such forward-looking statements. Words such as “believes,” “anticipates,” “planet,” “expects,” “intends,” “will,” “target,” “potentially” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Regulus’ current expectations and include assumptions that may never materialize or prove to be incorrect. Actual results and timing of events could differ materially from those anticipated in such forward-looking statements due to various risks and uncertainties, including, but not limited to, risks associated with the discovery, development and commercialization of safe and effective human therapeutics for use and in drive to build a business around such drugs; and feedback from the FDA. While Regulus expects the COVID-19 pandemic to adversely affect its operations and financial results, the magnitude of the impact will depend on Regulus’ ability to meet its preclinical and clinical development goals, as well as the value and market for its common stock depends on future developments that are highly uncertain and cannot currently be predicted with confidence, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing requirements and business closures in the US and other countries, and the effectiveness of measures taken worldwide to contain and treat the disease. These and other risks are fully described in Regulus’ filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date of their publication. Regulus assumes no obligation to update such statements to reflect events or circumstances that occur after the date of their publication.
View original content to download multimedia: https://www.prnewswire.com/news-releases/regulus-therapeutics-announces-timing-for-second-quarter-2021-financial-results-webcast-and-conference-call-301347375 .html
SOURCE Regulus Therapeutics Inc.